Selank Peptide: Benefits, Nasal Spray vs Vial, Dosage and Research

Selank peptide: benefits, nasal spray vs vial, dosage and research

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the tuftsin sequence with a Pro-Gly-Pro tail, developed at the Institute of Molecular Genetics in Moscow and studied for anxiety-related behaviour, cognition and immune markers. PrymaLab supplies it as a Selank 5mg vial, Selank 11mg vial, Selank 10mg Nasal Spray and preloaded Selank pen for research use.

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), seven residues, molecular weight about 751.9 g/mol.
• Class: synthetic tuftsin analogue and a sibling of Semax; see the Semax vs Selank comparison.
• Studied for: anxiety-related behaviour, GABAergic gene expression, enkephalin degradation, BDNF, IL-6 and other immune markers.
• Typical figures in the literature: 2.7 mg per day intranasally for 14 days in the Russian anxiety trials; 300 mcg/kg intranasally in rat studies.
• Storage: lyophilised vials frozen or refrigerated; spray and pen refrigerated, never frozen; reconstituted solution refrigerated.
• Forms and sizes at PrymaLab: Selank 5mg, Selank 11mg, Selank 10mg Nasal Spray, Preloaded Autoinjector | Selank | 3ml Pen | 1mg/ml.
• Reconstitution: the peptide reconstitution calculator turns vial size and diluent volume into mg per ml.

What Selank is and where it came from

Tuftsin is a four-residue peptide, Thr-Lys-Pro-Arg, that sits inside the heavy chain of immunoglobulin G. Najjar and Nishioka described it in 1970 at Tufts University, which is where the name comes from, as a fragment that stimulates phagocytosis in neutrophils and macrophages. By origin it is an immune peptide, and a short-lived one: free tuftsin is cut apart by aminopeptidases and carboxypeptidases within minutes of entering blood, which is one reason the natural fragment never became a drug in its own right.

Selank keeps the tuftsin core and slows that cutting. Chemists at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, working with pharmacologists at the Zakusov Research Institute of Pharmacology, added the tripeptide Pro-Gly-Pro to the C-terminus, giving the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Proline-rich tails are poor substrates for most peptidases, so the modified peptide survives longer in tissue than its parent. The same tail sits on Semax, the other peptide from the same laboratory, for the same reason.

Behavioural pharmacology at the Zakusov institute during the 1990s reported anxiolytic-type effects in mice and rats, and that work set the compound's direction. Russia went on to register Selank as a prescription nasal drop, a 0.15% solution containing 1.5 mg of peptide per millilitre, with anxiety states as the indication.

That registration is Russian only. Selank has no marketing approval from the FDA or the European Medicines Agency, and no regulator outside Russia has reviewed the trial data behind it. In the United States it is a research chemical, which is the basis on which PrymaLab supplies it: reference material for laboratory work, not a medicine.

Selank vs Semax

The two peptides get sold side by side and are often described as variations on one idea. They share a laboratory, a Pro-Gly-Pro tail and an intranasal route, and that is where the overlap ends. Semax is built on ACTH(4-7), a fragment of adrenocorticotropic hormone, and its research record is mostly about BDNF, NGF and ischaemic stroke. Selank is built on an immune peptide, and its record is mostly about anxiety-related behaviour and immune gene expression.

One practical difference does not show up in a sequence table. Semax begins with methionine, which oxidises in solution; Selank has no methionine, so it is the more forgiving of the two once reconstituted, although hydrolysis still applies and both are kept cold. The long-form Semax vs Selank comparison goes through the sequences, the amidate variants and the gap in accessible evidence between the two in detail.

What the research has looked at

Almost all of the Selank literature comes from two Moscow institutes, and much of it appears in Russian-language journals with English abstracts. That shapes how the findings should be read: samples are small, the clinical studies compared Selank with a benzodiazepine, and no group outside Russia has replicated the clinical results. With that in mind, the work falls into five threads.

GABAergic modulation

Volkova and colleagues (2016) gave rats a single intranasal dose of Selank at 300 mcg/kg and profiled 84 genes involved in neurotransmission in the frontal cortex. Forty-five of those genes had changed expression an hour after dosing and 22 at three hours, which the authors read as allosteric modulation of the GABAergic system. Kasian and colleagues (2017) ran rats through an unpredictable chronic mild stress protocol and reported that Selank combined with diazepam was the most effective condition for reducing anxiety in the elevated plus maze under stress, pointing at the same system. Vyunova and colleagues (2018) ran radioligand binding assays on brain cell membranes and reported that Selank acts on [3H]GABA binding as a positive allosteric modulator, and that it can block the modulatory activity of diazepam and olanzapine. The picture that emerges is of a peptide that modulates GABAergic signalling rather than acting as a direct agonist, which would fit the absence of sedation reported in the clinical work.

BDNF

Inozemtseva and colleagues (2008) reported that intranasal Selank raised BDNF expression in the rat hippocampus. This is the finding that connects Selank to the cognition claims found in vendor copy, and it is the same effect Semax is better known for. Beyond it, the cognition evidence for Selank is thin: a small number of rodent memory tasks, and human data that sit inside the anxiety trials as secondary measures.

Enkephalin degradation

Zozulya and colleagues (2001) showed that Selank inhibits enkephalin-degrading enzymes in human serum, and Kost and colleagues (2001) reported the same for Selank and Semax together. The proposed mechanism is simple: slower breakdown of leucine-enkephalin leaves more of the endogenous opioid peptide at its receptors, which could account for part of the anxiolytic-type effect. The 2008 clinical study measured leucine-enkephalin half-life in patient serum and reported that it rose during Selank dosing, most clearly in the patients with generalised anxiety disorder, the closest thing to a mechanistic marker in the human work.

IL-6 and immune findings

Selank's parent is an immune peptide, and the immune findings are the part of its record that Semax does not share. Uchakina and colleagues (2008) reported that Selank at 10^-7 M suppressed interleukin-6 gene expression in peripheral blood cells from patients but not from healthy controls, while IL-6 protein in the same cultures rose, and that the Th1/Th2 cytokine balance in serum shifted over 14 days of dosing in patients with generalised anxiety disorder and neurasthenia. The effects run in more than one direction, which is why the authors describe the peptide as a cytokine regulator rather than an IL-6 blocker. Kolomin and colleagues (2011) profiled inflammation-related genes in mouse spleen after Selank and reported altered expression across a group of cytokine and chemokine genes. Whether those changes matter for any immune endpoint has not been tested in a controlled trial.

The Russian clinical trials in generalised anxiety

Zozulya and colleagues (2008) enrolled 62 patients with generalised anxiety disorder or neurasthenia and compared intranasal Selank, given as 36 drops of the 0.15% solution a day (2.7 mg) in three divided doses for 14 days, against medazepam at 30 mg a day. The paper reports no principal difference in overall therapeutic effect between the two arms, a measurable drop in drowsiness on Selank, and no withdrawal syndrome or signs of dependence once it was stopped, against adverse effects in 65% of the medazepam patients. Medvedev and colleagues (2014) compared Selank at 2.7 mg a day with phenazepam at 2 mg a day over 14 days in 60 patients with anxiety-phobic, hypochondriac and somatoform disorders, and reported a pronounced anxiolytic effect that lasted a week beyond the last dose. Medvedev and colleagues (2015) then gave Selank alongside phenazepam in 40 patients, against 30 on phenazepam alone, and reported that the combination lowered the rate of phenazepam side effects such as sedation and attention and memory impairment, both during treatment and after the benzodiazepine was withdrawn.

These trials are the whole of the clinical record. They were run by the developers, published in Russian, and have not been repeated by an independent group. That does not make the findings wrong; it makes them unconfirmed, which is the accurate position for a compound sold as reference material.

Selank nasal spray vs vial

Intranasal is the route in every Russian clinical study, in the registered Russian product and in the rat BDNF work, so a nasal spray is not a marketing invention; it follows the literature. The lyophilised vial is the reference form for bench work, where the dose is calculated in mg/kg and the concentration is set by the researcher. PrymaLab supplies both, plus a preloaded pen.

The spray costs more per milligram than the vial because the dissolving and filling have been done already, and because the bottle meters the volume. For work that copies the intranasal route, that convenience is the point. For in vitro work, or any protocol that needs a concentration the spray does not provide, the vial is the better fit. The pen sits between the two: a fixed 1mg/ml solution, ready to inject, for laboratory protocols that use the subcutaneous route. What intranasal delivery does and does not achieve in general is covered in our post on whether peptide nasal sprays work.

Selank dosage in the literature

The table lists what published studies administered, by study, subject and route. The figures are reported study conditions, not a protocol, and PrymaLab supplies Selank for laboratory research only.

Two things about the units. The Russian trials express dose as milligrams per day delivered as nasal drops of a 0.15% solution, a fixed-volume format; the rodent work expresses dose per kilogram of body weight, by the same intranasal route. The two are not interchangeable, and converting between them needs allometric assumptions the papers do not make. Exposure length also differs between the animal studies themselves: Volkova gave a single dose, while Kasian dosed daily for 14 days, the same course length as the clinical trials.

Storage and handling

Lyophilised Selank is the stable form. Kept at -20°C, sealed and away from light, the powder holds for months; a refrigerator at 2 to 8°C is acceptable for shorter periods. Reconstitution uses bacteriostatic water added slowly down the inside wall of the vial, then gentle swirling rather than shaking, since foaming shears peptide chains. The solution goes back in the refrigerator and is not refrozen: repeated freezing and thawing degrades peptides faster than steady cold storage.

The nasal spray and the pen arrive in solution, so they skip reconstitution but also give up the stability advantage of dry powder. Both are refrigerated, never frozen, and kept out of light. An opened spray has a shorter working life than a sealed vial, and the labelled period on the bottle is the limit.

Selank has no methionine, so the oxidation problem that shortens the life of reconstituted Semax does not apply here. Hydrolysis and residual peptidase activity still do, which is why cold storage matters even for a peptide with a protective Pro-Gly-Pro tail. For the vial maths, the peptide reconstitution calculator gives the concentration for any vial size and diluent volume: 11mg in 2ml is 5.5mg/ml, and 5mg in 1ml is 5mg/ml.

Frequently asked questions

Key takeaways

• Selank is tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tail, a seven-residue synthetic peptide from the Institute of Molecular Genetics in Moscow.
• Its research record covers GABAergic gene expression, BDNF, enkephalin-degrading enzymes, IL-6 and immune markers, plus Russian clinical trials in generalised anxiety disorder that no independent group has repeated.
• Registration as an intranasal anxiolytic is Russian only; there is no FDA or EMA approval, and the compound is a research chemical in the United States.
• Intranasal is the route in the clinical work, which is why a pre-dissolved nasal spray exists alongside the lyophilised vial and the 1mg/ml pen.
• Literature figures cluster at 2.7 mg per day intranasally in the trials and 300 mcg/kg intranasally in rats; PrymaLab supplies every format for research use only.

Related products

• Selank 5mg
• Selank 11mg
• Selank 10mg Nasal Spray
• Preloaded Autoinjector | Selank | 3ml Pen | 1mg/ml
• Semax 10mg Nasal Spray

References

1. Najjar VA, Nishioka K. "Tuftsin": a natural phagocytosis stimulating peptide. Nature. 1970;228(5272):672-673. PubMed
2. Zozulya AA, Kost NV, Sokolov OY, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. PubMed
3. Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-183 (in Russian). PubMed
4. Zozulya AA, Neznamov GG, Syunyakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48 (in Russian). PubMed
5. Uchakina ON, Uchakin PN, Myasoedov NF, et al. Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75 (in Russian). PubMed
6. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PubMed
7. Kolomin T, Shadrina M, Andreeva L, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23. PubMed
8. Medvedev VE, Tereshchenko ON, Israelyan AY, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22 (in Russian). PubMed
9. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40 (in Russian). PubMed
10. Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PubMed
11. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behav Neurol. 2017;2017:5091027. PubMed
12. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018;25(10):914-923. PubMed